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Arteriovenous fistula construction in the thigh
with transposed superficial femoral vein: 
Our initial experience
Wayne S. Gradman, MD, William Cohen, MD, and Massoud Haji-Aghaii, MD, Los Angeles, Calif
Purpose: The National Kidney Foundation–Dialysis Outcomes Quality Initiative guidelines favor autogenous vein for
arteriovenous fistulas (AVFs). This report describes our experience constructing AVFs in the lower extremities of
selected patients with the superficial femoral vein (SFV).
Patients and Methods: This is a retrospective analysis of 25 patients who had AVF construction with SFV from March
1998 to July 2000. In all patients upper extremity access had been exhausted. Eighteen (72%) patients were female, 15
(60%) had diabetes, and 14 (56%) were obese (body mass index > 30 kg/m2). The SFV was freed from the supragenic-
ular popliteal level to the profunda femoris vein and divided distally. Eighteen (72%) patients had SFV transposition and
distal superficial femoral artery reimplantation; 10 veins were banded to reduce the incidence of postoperative steal syn-
drome. In seven patients (28%) a composite loop fistula was constructed with a deeply buried 4- to 7-mm polytetraflu-
oroethylene (PTFE) graft proximally and with superficially transposed SFV distally. One of these seven patients had a
PTFE above-knee femoral-popliteal bypass graft with banding of the vein at its takeoff from the distal PTFE graft.
Results: Mean follow-up was 9.1 months. One patient died before the fistula could be used. Seven patients (28%) expe-
rienced major wound complications. Mean ankle/brachial index before operation was 1.03, and after operation it was
0.81 (paired difference [n = 16] = –0.26.) Mean ankle circumference before operation was 19.5 cm, and after opera-
tion it was 20.7 cm (paired difference [n = 17] = +0.87.) Cumulative primary fistula patency at 6 and 12 months was
78% and 73%, respectively. Cumulative secondary fistula patency at 6 and 12 months was 91% and 86%, respectively.
There were no fistula infections. One patient eventually had an above-knee amputation after experiencing an acute com-
partment syndrome. Eight patients required a second operation to alleviate a symptomatic steal syndrome.
Conclusions: The SFV is an excellent conduit for vascular access, whether it is transposed or is part of a composite PTFE-
SFV fistula. In this series, fistula infection was nonexistent, thrombosis rates were low, and clinical evidence of venous
hypertension was minimal. The major impediment to unrestricted use of SFV in constructing AVFs is a high incidence
of clinically significant postoperative ischemia requiring reoperation. (J Vasc Surg 2001;33:968-75.)
A steady increase in the number and age of patients
undergoing hemodialysis has emphasized the need to con-
struct durable arteriovenous access. Multiple factors con-
tribute to the exhaustion of access sites, including intimal
hyperplasia of axial veins, liberal and prolonged use of central
venous and peripherally inserted central catheters, infections,
and pacemaker leads. Although Dialysis Outcomes Quality
Initiative (DOQI) guidelines favor autogenous vein for arte-
riovenous fistulas (AVFs),1 we have been disappointed with
the saphenous vein as an access conduit. The superficial
femoral vein (SFV) has proved useful in a variety of settings
favoring a large venous conduit.2-4 This report describes our
experience constructing AVFs in the lower extremities with
transposed SFV (tSFV).
PATIENTS AND METHODS
This is a retrospective analysis of 25 patients who had
AVF construction in the lower extremities with autolo-
gous tSFV from March 1998 to July 2000. Follow-up was
complete on all patients. In each patient upper extremity
AVF or arteriovenous graft (AVG) access had been
exhausted in the opinion of one of three senior vascular
surgeons, who were based at a large urban private teach-
ing hospital. Twenty-one patients had documented uncor-
rectable stenosis or occlusion of the bilateral subclavian or
more central veins, including the superior vena cava. One
superobese patient had “extremely small arm veins.”
Three patients had just undergone removal of an infected
polytetrafluoroethylene (PTFE) graft from the upper arm
with resultant narrowing of the axillary vein.
Criteria for proceeding with a tSFV fistula rather
than a loop PTFE bridge fistula varied by surgeon, but
primary consideration was given to using tSFV whenever
access was restricted to one leg and the patient was
deemed sufficiently healthy to undergo the procedure
and benefit from durable access. Patients with both legs
available for construction of a new access were preferen-
tially selected for tSFV access when there was a history of
an infected AVG in the upper extremities, or the patient
was relatively young.
The patient demographics and characteristics chosen
for study are listed in the Table. Each patient’s age, sex, and
history of diabetes were compared with the prevalent pop-
ulation parameters of patients with end-stage renal disease
(ESRD) in 1997.5 Body mass index (BMI) was compared
with new patients with ESRD in 1997.6 We used the
National Heart, Lung, and Blood Institute’s definitions for
the cutoff points between overweight (BMI 25.0-29.9
kg/m2) and three class levels of obesity (class 1, BMI 30.0-
34.9 kg/m2; class 2, BMI 35.0-39.9 kg/m2; class 3, BMI
> 40.0 kg/m2.)7 Preoperative duplex studies, both arterial
and venous, and arteriograms were obtained at the discre-
tion of the attending surgeon. A venogram was routinely
obtained when the patient previously had either a long-
standing femoral dialysis catheter or a loop PTFE graft with
a venous revision or repair. A leg was determined unusable
for access if venography showed occlusion or high-grade
stenosis of the iliac veins, if the surgeon determined the
groin to be “hostile” (numerous previous vascular proce-
dures), or if phlebitis had affected the SFV. The saphenous
vein was considered occluded if it had been harvested or
previously used for access outflow. Patients with amputa-
tions at the below-knee or higher level were excluded from
analysis of the relation between AVF construction and steal
syndrome. Ankle/brachial indices (ABIs) and ankle circum-
ferences (in centimeters) were determined before and at
least 1 month after construction of the fistula. Patients were
excluded from ABI analysis for vascular calcification.
Technique (Fig 1). An incision was made over the SFV
from the inguinal crease to just above the knee. The sar-
torius muscle was mobilized sufficiently to harvest the
underlying vein. Care was taken to preserve as many
femoral artery branches as possible. At this point one of
two operations was chosen.
SFV transposition. Our preference in a patient with
pedal pulses and an ABI more than 0.85 was to transpose
the vein to a superficial position and reimplant it on the
distal femoral artery (n = 18). The adductor magnus ten-
don was divided. The length of the vein harvested
depended on the size of the patient. Thin patients required
considerably less vein than obese patients, whose dissection
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often extended to the limit imposed by the medial head of
the gastrocnemius muscle. The SFV was divided distally
and freed to the profunda femoris vein, at which level the
vein lies more posterior than medial to the femoral artery.
The vein was transposed deep to the femoral artery and
then tunneled laterally to the skin through a small incision.
A second incision was made about 15 cm distal to the first,
and a tunnel parallel to and about 4 cm from the main skin
incision was created with a Scanlan tunneler (Scanlan
International, Inc, St Paul, Minn).
The vein was tunneled back to the femoral artery
approximately midway between the adductor tendon and
the sartorius muscle. The vein was then implanted end to
side on the artery in standard fashion. The immediate
effect of the fistula on the distal circulation was assessed
with pulse palpation and Doppler flow. The vein was
suture banded if the surgeon subjectively determined that
the distal circulation was compromised or if the flow in the
fistula seemed inordinately high. Incisions were closed in
layers without drains.
Loop composite PTFE and tSFV fistulas. If pedal
pulses were absent, the ABI was less than 0.85, or the
superficial femoral artery was heavily calcified, a composite
PTFE-tSFV loop fistula was created (n = 6). Less vein was
needed for this procedure than for the tSFV fistula, because
the SFV was not extended to the superficial femoral artery.
The vein was divided distally, transposed lateral to the
femoral artery, and tunneled to the skin through a small
incision. A second incision was made about 15 cm distal to
the first, and a subcutaneous tunnel parallel to the skin inci-
sion was created. The vein was now tunneled to this more
distal incision. A 4- to 7-mm ringed PTFE fistula (usually
tapered to 5 mm) was implanted on the common femoral
artery and tunneled in loop fashion to the end of the SFV.
The PTFE graft was tunneled deep beneath the skin to pre-
vent routine needle access and lateral to the vein to elimi-
Patient characteristics: selected comparisons with 1997 USRDS population
Composite USRDS
Characteristic tSFV (n = 18) PTFE-tSFV (n = 7) Total (n = 25) 1997 population 
Age (y ± SEM) 52.6 ± 4.1 62 ± 4.3 55.2 ± 3.3 565
Sex
Male 5 2 7 (28%) 53.1%*5
Female 13 5 18 (72%) 46.9%*5
Diabetes 9 6 15 (60%) 44.4%5
BMI (kg/m2 ± SEM ) 30.9 ± 2.5 33.2 ± 4.8 31.6 ± 2.2 25.9*6
< 30.0 8 3 11 (44%)
30.0-34.9 3 2 5 (20%)
35.0-39.9 4 0 4 (16%)
> 40 3 2 5 (20%)
Current IV drug use 2 0 2 (8%)
> 15 y ESRD 3 1 4 (16%)
Ipsilateral amputation 1 2 3 (12%)
Saphenous vein unusable 5 3 7 (32%)
Only one limb usable for AVF 9 6 15 (60%)
Preoperative ABI 1.05 ± 0.05 (n = 14) 1.00 ± 0.21 (n = 4) 1.03 ± 0.06 (n = 18)
*P < .05.
ABI, Ankle/brachial index; AVF, arteriovenous fistula; BMI, Body mass index; ESRD, end-stage renal disease; IV, intravenous; PTFE, polytetrafluoroethyl-
ene; tSFV, transposed superficial femoral vein; USRDS, US Renal Data System.
nate the PTFE graft traversing the main incision. End-to-
end anastomosis of PTFE graft and SFV was accomplished,
and flow was restored. The distal circulation was assessed
intraoperatively with pulse palpation and Doppler flow.
Incisions were closed in layers without drains.
One patient had an above-knee femoral-popliteal
bypass graft with PTFE and simultaneous construction of
an AVF with tSFV implanted on the distal PTFE graft. For
data analysis this patient is included among those who had
construction of a composite PTFE-tSFV loop fistula.
The following outcomes were analyzed: incidence and
nature of wound complications, preoperative and postop-
erative ankle circumference (in centimeters) and ABI, pri-
mary and secondary fistula survival, ischemic complications
requiring repeat surgery, and other complications.
Statistical methods included the Student t test and the χ2
tables for group comparisons, the Kaplan-Meier technique
for fistula patency, and univariate analysis with the Cox
proportional hazards model for variables possibly affecting
the need for surgery to correct a steal syndrome. A P value
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Fig 1. A, Mobilized SFV is passed deep to superficial femoral artery and brought to skin laterally. B, SFV is tunneled distally. 
A
B
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less than .05 was accepted as significant. Statistic sum-
maries are expressed as the value ± SEM.
RESULTS
Patient population. The Table summarizes the
patient demographics and characteristics of the 25
patients. The prevalence of female sex and diabetes, and
the mean BMI show a significant difference from compa-
rable population parameters of patients with ESRD
reported by the US Renal Data System. Columns 2 and 3
in the Table show no significant difference in characteris-
tics between patients undergoing the two basic surgical
Fig 1 contd. C, Completed SFV transposition. D, Composite PTFE-transposed SFV loop fistula. PTFE is tunneled deeply to deter can-
nulation of synthetic material. PTFE, Polytetrafluoroethylene.
C
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variations. We therefore combined these two groups for
statistical analysis.
Procedure. The SFV was banded at the time of
surgery in 10 of 18 patients having tSFV surgery. One
patient had a dominant profunda femoris vein with a rela-
tively small 4-mm SFV that was successfully accessed for 8
months before occlusion. Seven patients had a composite
loop PTFE-tSFV fistula, one of whom had a PTFE
femoral-popliteal bypass graft with a banded tSFV origi-
nating from the distal portion of the graft. Fistulas were
accessed from 3 days to 4 months after surgery.
Outcome. Mean follow-up was 9.1 months (range,
1.0-20.5 months) for all 25 patients, 9.4 months for the
18 patients with a tSFV fistula, and 8.4 months for the 7
patients with a composite loop PTFE-tSFV fistula. One
patient (combined femoral-popliteal bypass graft and
tSFV) died a month after surgery, before the fistula was
used. Three additional patients died at 5, 8, and 9 months
after surgery. Seven patients had significant wound com-
plications that prolonged either hospitalization or postop-
erative recovery. These included 3 patients with extensive
partial or full-thickness eschars, 2 with wound infections,
1 with a lymphocele, and 1 with all three. All eschars
appeared on the medial aspect of the thigh incision and
did not affect the fistula, which in all cases was tunneled
laterally. Each eschar healed secondarily without debride-
ment or skin grafting.
The mean preoperative ankle circumference (n = 19)
was 19.5 ± 0.7 cm; the postoperative ankle circumference
(n = 17) was 20.7 ± 0.8 cm. The mean paired difference
in 17 patients was 0.87 cm with a 95% CI between –0.1
and 1.9 cm. The mean preoperative ABI (n = 18) was 1.03
± 0.06; the postoperative ABI (n = 16) was 0.81 ± 0.07.
The mean paired difference in 16 patients was –0.26 with
a 95% CI between –0.38 and –0.14. Failure to measure
paired ABI differences was due to previous amputation
(3), preoperative failure to measure (3), death (1), fistula
revision or failure before the repeat measurement (1), and
arterial calcification (1).
Primary patency for all patients was 78% and 73% at 6
and 12 months, respectively. Secondary patency was 91%
and 86% at 6 and 12 months, respectively (Fig 2). Four fis-
tulas thrombosed and were repaired, two fistulas under-
went repair while still patent (data incorporated among
patients who had successful thrombectomy of a throm-
bosed fistula), and one fistula was ligated. Two of four
repaired thrombosed fistulas later reoccluded and could
not be reopened.
Eight patients required a second operation to correct
the effects of a steal syndrome. Univariate analysis of pre-
operative and postoperative covariates, including fistula
configuration, revealed that the only covariate with a P
value less than .15 was age (P = .0508). The regression
coefficient was 0.053 with a 95% CI of –0.007 to 0.112.
None of the five patients aged 40 years or younger expe-
rienced an ischemic complication.
One female diabetic smoker who had a loop com-
posite PTFE-tSFV fistula had an acute anterior compart-
ment syndrome in the immediate postoperative period
that was not promptly recognized. This patient had a fas-
ciotomy on the third postoperative day, stenting of an
unexpected iliac artery stenosis, and a femoral-popliteal
bypass graft. She eventually underwent an above-knee
amputation for anterior compartment muscle necrosis
and infection. The fistula, however, has continued in use.
One obese diabetic female patient had banding of the fis-
tula on the fifth postoperative day (tSFV) for sympto-
matic foot ischemia and a foot drop, which developed
without a tense or tender anterior compartment. Nerve
conduction studies showed complete loss of peroneal
nerve function. The six additional reoperative procedures
for symptomatic ischemia included three above-knee
femoral-popliteal bypass grafts at 2, 6, and 13 months; a
femoral-tibial bypass graft at 3 months; fistula ligation at
4 months (in conjunction with a lymphocele, eschar, and
ischemic foot); and conversion of a tSFV to a loop com-
posite PTFE-tSFV fistula at 7 months. Interval ligation
was not done with any bypass graft.
Fig 2. Cumulative primary and secondary/assisted patency for 25 fistulas with SFV.
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not be available if a synthetic loop bridge graft were con-
structed first.
Our complication rate, however, was strikingly high.
Although we anticipated that many complications would
reflect the consequences of venous hypertension, edema
was a significant problem for only one patient. Most of our
complications involved wound healing and, more impor-
tant, limb-threatening distal ischemia.
Wound complications were frequent in this series.
Several patients had multiple, prior, lower extremity access
and revascularization procedures, and the groin and thigh
were often crisscrossed with incisions. The patients with
deep eschars were seen early in our series. As the series
progressed, we selected individuals before they had place-
ment of multiple ipsilateral grafts. In an attempt to pre-
serve as much arterial flow to the thigh tissues as possible,
we meticulously avoided femoral artery branch division
when harvesting the vein, even though the vein lies behind
the artery throughout the length of the thigh. We
nonetheless have no illusion that wound complications
would ever disappear in this population of patients, which
would probably always contain a disproportionate number
of obese diabetic patients. Wound complications were suc-
cessfully managed in routine fashion except in one indi-
vidual whose fistula was ligated in the presence of wound
breakdown and distal extremity ischemia. 
The most disappointing outcome of this series was a
high frequency of early and late-appearing ischemic com-
plications. One patient had a classic case of compartment
syndrome, with a tense anterior compartment on the sec-
ond postoperative day requiring fasciotomy and eventual
above-knee amputation. A second patient had peroneal
nerve palsy in the absence of an obvious case of clinical
compartment syndrome, possibly as a result of ischemia.
We are unaware of previous reports of compartment syn-
dromes after construction of lower extremity access. One
possible explanation for its appearance in this series is that,
in addition to the obligatory arterial steal after AVF con-
struction, these patients have the additional burden of dis-
tal venous hypertension, which in itself can be a cause of
increased compartment pressure requiring fasciotomy.14
Indeed, individuals sustaining traumatic vascular disrup-
tion of both the axial artery and vein commonly have com-
partment syndromes.15
Symptomatic distal leg ischemia (steal syndrome)
appeared from 3 days to 12.8 months after surgery. After
the immediate postoperative period, we preferred to relieve
the steal syndrome with a distal bypass graft, rather than
risk incomplete reversal of the ischemia or jeopardize the
fistula with additional banding. Interval ligation (distal
revascularization–interval ligation procedure) was never
done and did not appear necessary.16
The incidence of distal ischemia after arteriovenous
bridge graft construction in the lower extremities is
markedly higher than in the upper extremities and is usu-
ally attributed to the higher prevalence of arteriosclerotic
occlusive disease in the lower extremities.11,17 In a study of
45 patients who had lower extremity bridge grafts and
No tSFV or composite PTFE-tSFV fistula became
infected during the study period. One patient had total
occlusion of the ipsilateral iliac vein 8 months after fistula
construction. The iliac vein underwent thrombolysis and
stenting without interruption of fistula access. A second
patient had stenting of the ipsilateral iliac vein at 3 months.
DISCUSSION
Numerous solutions for patients in whom access is diffi-
cult have been reported, including fistulas based on the axil-
lary and jugular vessels, use of the saphenous vein, and
long-term central venous catheters.8-10 We have been disap-
pointed with each of these modalities, because of either lim-
ited applicability or frequent failures. When upper extremity
access is exhausted, a loop arteriovenous thigh bridge graft
is usually constructed. Objective analysis of these grafts,
however, has shown a high complication and failure rate.11
Our increasing experience and familiarity with the SFV
in a variety of clinical settings, along with the DOQI guide-
lines,1 persuaded us to consider using the SFV for dialysis
access in patients with difficult access. Our preference was
to construct a tSFV similar in configuration to a transposed
basilic vein. When that configuration was not feasible, our
second choice was to construct a loop composite PTFE-
tSFV fistula that was based on the common femoral artery.
In each instance, the goals were to allow access only
through the SFV and prevent routine cannulation of PTFE,
which we think is the major reason for graft infection and a
common cause for frequent revision. There was little or no
difference in demographics or outcome between patients
undergoing tSFV versus those undergoing a loop compos-
ite PTFE-tSFV fistula. This lack of significance may reflect
the small number of patients who had a loop composite fis-
tula and could change with study of a larger series.
Previous studies indicate that the population of “diffi-
cult access” patients includes more who are female and are
diabetic than those in the general hemodialysis popula-
tion.12 Our personal experience had suggested that obese
patients also have a higher incidence of fistula infection
and failure than other patients undergoing hemodialysis.
We therefore included the BMI in each patient’s demo-
graphic data. Compared with comparable parameters in
the national ESRD population,5,6 the admittedly selected
individuals in our treatment group show a significantly
increased prevalence of female sex, diabetes, and elevated
BMI. Additional acknowledged characteristics resulting in
exhaustion of upper extremity access include intravenous
drug addiction and hemodialysis longevity, each of which
is well represented in our treatment group.
Our results show that fistula patency and freedom
from infection closely resemble those of autogenous vein
fistulas in the upper extremities.13 For many of our
patients, the SFV-based fistula was the most durable access
they ever had. Furthermore, to a patient literally down to
the last access extremity, it was comforting to learn that
one more access option was available should the SFV fis-
tula fail, namely, a loop bridge graft that was based on the
common femoral artery and vein. A fallback option might
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were followed up for 5 years, Taylor et al11 documented
distal limb ischemia in seven (16%) patients, three of whom
required major lower limb amputations. Our ischemic
complication rate appears to exceed even theirs. Balanced
against that, however, is their 6- and 12-month primary
graft patency of 67% and 52% versus our 78% and 73%,
respectively, and a graft infection rate of 18% versus our 0%.
Although univariate analysis revealed no statistically sig-
nificant covariate influencing development of the steal syn-
drome (P < .05), the data trend suggests that younger
patients are relatively resistant to it. Elastic arteries, in con-
trast to diabetic or calcified arteries, dilate to accommodate
the increased flow needed to mitigate a steal syndrome.18,19
As our early and late ischemic complications accumu-
lated, we acknowledged the inadequacy of selectively
banding the SFV solely on the basis of intraoperative
assessment of distal pulse palpation and Doppler flow. We
continuously sought ways to avoid steal syndromes yet not
compromise fistula patency. Our current practice is to (1)
obtain preoperative arteriograms in all patients except
those with bounding pulses, (2) routinely taper the SFV to
5 mm at its takeoff from the femoral artery with the aid of
a Hegar dilator (J. Rosental, MD, oral communication,
May 2000), and (3) directly measure the intra-arterial
pressure of the distal femoral artery16 after constructing
the fistula. We think that corrective measures are necessary
if the distal femoral artery pressure is less than half the
brachial artery pressure.
Although the excellent patency rate and absence of
infections in this series of difficult access patients are
encouraging, the high incidence of ischemic complications
requiring a distal bypass graft currently dissuades us from
recommending use of the SFV as a primary procedure for
individuals having their first lower extremity access. When
access is limited to a single leg, however, the SFV, either
transposed or part of a composite fistula, should be con-
sidered in suitable patients. Construction of a conven-
tional PTFE loop bridge graft is always possible later.
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Dr Kenneth McIntyre (Dallas, Tex). There are almost a quar-
ter of a million patients with end-stage renal disease (ESRD) in this
country who depend on hemodialysis for survival, and this popula-
tion is increasing yearly. Even with a mortality rate of 20% per year,
hemodialysis patients are living longer, challenging vascular sur-
geons to utilize unconventional techniques to construct arteriove-
nous fistulas (AVFs). It is well accepted that AVFs have the fewest
complications and the best patency and durability. Unfortunately,
however, AVFs account for only 25% to 30% of all permanent
accesses. As recently as 1993, 75% of hemodialysis patients had
prosthetic bridge grafts. Almost 25% of hospitalizations for patients
with end-stage renal disease (ESRD) are related to vascular access,
and the cost of creating and maintaining angioaccess approaches a
staggering $1 billion annually. These numbers have caught the
attention of the National Institute of Diabetes and Digestive and
Kidney Diseases who are planning to fund five large centers to
study and hopefully improve hemodialysis access patency.
Dr Gradman and his colleagues have utilized a new technique
of creating an AVF in the thigh for hemodialysis using the super-
ficial femoral vein (SFV). We have had an interest in the SFV for
both arterial and venous reconstructions, and from the extension
of that work, we also have used the vein as a conduit to create an
DISCUSSION
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AVF for hemodialysis. I have a few observations and questions for
the authors.
First of all, the candidates for this procedure in the authors’
series included patients who were obese, with a high incidence
of female gender and diabetes. Moreover, each patient had
exhausted his/her alternatives for upper extremity access. It has
been my experience that the basilic vein is often perfectly nor-
mal, even in patients who have undergone multiple upper
extremity bridge grafts, and duplex scan is an excellent method
of determining its suitability for AVF. What objective tests, if
any, were used to determine if either the basilic or cephalic veins
were unsuitable?
I was surprised that the authors relied on venography to
determine whether the SFV was suitable for use. We routinely use
the duplex scan preoperatively for that purpose. Why wasn’t
duplex scanning used to evaluate the SFV?
I enjoyed the description of the surgical technique and rec-
ommend it to you for review. We perform the procedure in a sim-
ilar fashion, but have not used composite grafts with PTFE as was
done with seven patients in this series or banding as was used in
10 of 18 (56%). What were the criteria used to perform banding
of the SFV in your patients, and did this banding contribute to
thrombosis in any of the cases? The maturation time (operation
to first use) varied between 3 days and 4 months. How did you
decide when to cannulate the fistula for the first time?
Postoperatively, ankle circumference increased by about 1
cm, and we have noted similar mild swelling in our patients
undergoing this procedure. We also expect to see a decline in ABI
of about 20% as was noted in this series. Leg ischemia requiring
secondary operations occurred in eight (32%), and five of these
had been banded. Clearly, we really don’t understand who will or
will not develop ischemia following one of these procedures. Four
AVF thrombosed, and I was surprised that the authors tried to
thrombectomize these. Two of these subsequently thrombosed.
We have treated these like thrombosed saphenous vein grafts and
have not tried to perform thrombectomy, but preferred to aban-
don the thrombosed AVF. The primary patency at 6 and 12
months was 78% and 73%, respectively, which is really inferior to
results of brachiobasilic and/or brachiocephalic AVF in the upper
extremity. We have lost five of 11 SFV-AVF in the thigh because
of thrombosis, and because of this unacceptably low patency, we
have virtually abandoned use of the SFV in the thigh in favor of
placing it in the arm, which we have done in eight cases.
I enjoyed reading this manuscript and hearing the presenta-
tion, and I thank the program committee for the invitation to dis-
cuss it. I complement the authors on taking on a difficult group
of patients with an innovative approach and urge them to con-
tinue their work in this area. I look forward to an update from Dr
Gradman and colleagues on the progress of these patients in the
future. Thank you.
Dr Wayne S. Gradman. Thank you, Dr McIntyre. Most of
these patients lost their upper extremity access because of central
venous problems and not because they didn’t have usable basilic
and cephalic veins. We use duplex liberally in the upper extremi-
ties to determine if patients have usable veins, and we would cer-
tainly use them whenever possible. 
We tend to initiate access in the upper arm rather than the
forearm, and so we probably run out of access sooner than other
surgeons who start in the forearm. By the time we have finished
with the basilic, brachial, and cephalic veins in the upper arm,
there are few options available for constructing more grafts in the
arm. You simply run out.
We used venography and venous duplex scans selectively.
Venography was done primarily to rule out disease of the com-
mon femoral vein and the iliac vein, not to determine the patency
of the superficial femoral vein. That was done by duplex whenever
there was an indication.
Two patients persuaded us to use venous duplex routinely.
One patient had a routine duplex and was unexpectedly found to
have a recanalized superficial femoral vein. A second patient had
a dominant profunda vein. By the time we realized that the pro-
funda vein was dominant, we had dissected out the superficial
femoral vein and it was too late. We did use the relatively small
superficial femoral vein, but it thrombosed after 8 months and we
could not reopen it. 
Banding was left to the discretion of the surgeon. As you
know from experience with the upper extremity, it can be very dif-
ficult to determine what the right amount of banding is. I can
think of one patient whose fistula clotted because of overbanding.
This patient had significant tibial artery disease. We deliberately
overbanded the fistula, but it clotted. We then unbanded it, but
eventually she required a tibial artery bypass. Some of these
patients have had quite a few operations.
There must be more reliable ways to determine the right
amount of banding. We have started to use better surgical tech-
niques than just suturing the proximal fistula after constructing it.
We also like the idea of measuring the pressure in the distal
femoral artery after constructing the fistula and comparing it with
the arm pressure. This was discussed in a paper by Dr Berman in
evaluating how to manage the steal syndrome at the time of
surgery, and we tried it. We think it may turn out to be a very use-
ful modality. More liberal preoperative arteriography would also
be useful when you consider the patient who had the occult iliac
artery disease. 
We seldom abandoned a fistula once it clotted. We were able
to salvage some for the long term. Sometimes the reason they clot
is quite simple: a mechanical problem immediately after surgery.
That’s when most of the fistulas clotted.
One patient clotted a composite loop fistula immediately
after a 6-hour hip operation during which her pressure was 70 for
much of the time. When the anastomosis between the vein and
the PTFE was opened, the vein was completely patent, and it was
only the PTFE that had thrombosed. It was a simple matter to
clean out that graft and reestablish flow. 
Dr Kaj Johansen (Seattle, Wash). Desperate measure are
required when you’re in desperate straights, and you are to be
commended for providing us another tool for our tool kit in this
regard. I have two questions very briefly.
You had what all of us and you yourself would agree are
excessive wound complications and excessive ischemic complica-
tions. Those were the two bugaboos of this problem here. My
first question is are there any minimally invasive approaches, for
example, endoscopic approaches for perhaps dissecting the super-
ficial femoral vein as are readily available for the saphenous vein
that might be of use here?
Second, we have abandoned banding. As your own experi-
ence demonstrates, and I think many others as well, it is an
entirely unpredictable approach risking either failure of reduction
of flow or thrombosis. Is it not a reasonable alternative just to
consider an up-front drill procedure, a so-called distal revascular-
ization interval ligation, essentially converting of this thing in an
end-to-end fistula and bypass right at the same time?
I think that has been in our hands and in the literature virtu-
ally 100% successful at avoiding distal ischemic complications and
may well obviate the problems that you’ve reported.
Dr Gradman. I don’t think we will soon be able to use endo-
scopic procedures to dissect out the superficial femoral vein as we
can the saphenous vein. The superficial femoral vein is deeply
placed in a tight fascial compartment, and it has many branches.
I think it would be a troublesome entity to dissect out endoscop-
ically.
I still believe there’s a role for banding. I think we simply
have to learn how to use it to modulate flow and determine how
much is enough at the time of surgery. We don’t generally do that
in the upper extremities, but here it is obviously of critical impor-
tance. 
It’s interesting that in this series we did not use interval liga-
tion, the IL part of the DRIL procedure, in any of our patients.
We simply did the bypass procedure and that was more than ade-
quate to relieve ischemia in each instance. 
